FDA Forced OTC Switch Process Ambiguities Revealed At Subcmte. Hearing

FDA does not have an established procedure in place to prevent the disclosure of protected trade secrets in the event of a forced Rx-to-OTC switch, Center for Drug Evaluation & Research Director Janet Woodcock, MD, told a House panel June 13.